Pharmaceuticals

REGENT PACIFIC

REGENT PACIFIC released FY2025 9 Months Earnings on March 26 Post-Market (BJT), actual revenue HKD 2.342 M, actual EPS HKD -0.1083

REGENT PACIFIC released FY2025 Q3 earnings on March 26 (BJT), actual revenue HKD 490.31 K, actual EPS HKD -0.0332

REGENT PACIFIC released FY2025 Q4 earnings on March 26 During-Market (BJT), actual revenue HKD 490.13 K, actual EPS HKD -0.0331

REGENT PACIFIC released FY2025 Annual Earnings on March 26 During-Market (BJT), actual revenue HKD 2.831 M, actual EPS HKD -0.1404

REGENT PACIFIC to Release FY2025 Earnings Report on March 26 During-Market BJT

Deep Longevity Plans to Enter the US Market in Q1 Next Year

REGENT PACIFIC released FY2025 Q1 earnings on August 27 (BJT), actual revenue HKD 921.85 K, actual EPS HKD -0.0373

REGENT PACIFIC released FY2025 Semi-Annual earnings on August 27 During-Market (BJT), actual revenue HKD 1.852 M, actual EPS HKD -0.075

REGENT PACIFIC released FY2025 Q2 earnings on August 27 During-Market (BJT), actual revenue HKD 930.21 K, actual EPS HKD -0.0377

REGENT PACIFIC FY2025 Semi-Annual Earnings Release on August 27, 2025 (BJT)

Lazada Pacific Completes Debtor-in-Possession Agreement and Issues Shares to Galloway

Lijung Pacific signs debt settlement agreement with Galloway, issuing 63,377,163 capitalization shares

REGENT PACIFIC released FY2024 9 Months Earnings on March 27, 2025 (BJT), with actual revenue of HKD 3.588 M and EPS of HKD -0.1213

REGENT PACIFIC released FY2024 Q3 earnings on March 27 (BJT), actual revenue 2.627 M HKD, actual EPS -0.0316 HKD

Regent Pacific released FY2024 Q4 earnings on March 27 After-Market (BJT), actual revenue 2.625 M HKD, actual EPS -0.0316 HKD

REGENT PACIFIC released FY2024 annual earnings on March 27 After-Market (BJT), actual revenue 5.603 M HKD, actual EPS -0.1529 HKD

Jiangsu Wanbang Biochemical's New Drug Application Passes First Stage Review by National Medical Products Administration

REGENT PACIFIC FY2024 Annual Earnings Release Scheduled for March 27, 2025, After-Market BJT

Lijing Pacific and Jiangsu Wanbang Biopharmaceutical Collaborate to Apply for New Drug Senstend™

REGENT PACIFIC released FY2024 Q1 earnings on August 28, 2024 (BJT), with actual revenue of HKD 481.27K and EPS of HKD -0.0449

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

00575

Regent Pacific Group Limited is seeking shareholder approval for a new restricted share unit (RSU) incentive scheme aimed at rewarding key contributors and attracting talent. This initiative is part of the company's strategy to align employee interests with shareholders and enhance operational stability. Approval is required from shareholders at the upcoming annual general meeting and the Hong Kong Stock Exchange's Listing Committee. If successful, the RSU scheme could improve the company's competitiveness in the labor market and strengthen the link between management performance and shareholder value.

Tip Ranks

Regent Pacific Seeks Shareholder Approval for New RSU Incentive Scheme

Endurance RP (HK:0575) reported its 2025 results, focusing on its strategy to generate royalties through out-licensing its drug portfolio. The company aims for approval of Senstend in China by June 2026, in partnership with Wanbang Biopharmaceutical. Endurance RP is also advancing its AI-driven longevity technologies, positioning Deep Longevity as a key future driver. The latest analyst rating for the stock is a Hold with a price target of HK$0.93. The company has a market cap of HK$245.1M and a year-to-date price performance of -21.50%.

Endurance RP Sets Sights on China Approval and Longevity Tech Growth After 2025 Results

REGENT PACIFIC announced that its wholly-owned subsidiary "Deep Longevity, Inc." and its affiliates will launch an expansion plan into the United States in the first quarter of next year, driven by globally explainable artificial intelligence aging clocks. The group stated that this move will position "Deep Longevity" at the core of the largest and fastest-growing health market in the world, which is currently valued at over $6.8 trillion

AASTOCKS

REGENT PACIFIC's wholly-owned subsidiary will launch its expansion plan into the United States in the first quarter of next year

According to the Zhitong Finance APP, REGENT PACIFIC released its interim results for the six months ending June 30, 2025, with group revenue of USD 237,000, a year-on-year increase of 92.68%; net loss of USD 2.215 million, a year-on-year narrowing of 15.49%; and a loss per share of 0.961 US cents

Zhitong

REGENT PACIFIC released its interim results, reporting a net loss of USD 2.215 million, a year-on-year narrowing of 15.49%

REGENT PACIFIC announced that its partner Jiangsu Wanbang Pharmaceutical is advancing the new drug application for SenstendTM, having received the first round of inquiries from the National Medical Products Administration and submitted responses. Jiangsu Wanbang Pharmaceutical expects to obtain approval by the end of 2025 and launch in the first quarter of 2026. Meanwhile, Deep Longevity has made progress in expanding new clients and plans to enter the U.S. market to promote the application of longevity and health technology

REGENT PACIFIC: Jiangsu Wanbang Pharmaceutical is advancing the new drug application for SenstendTM with the National Medical Products Administration of China

REGENT PACIFIC(00575.HK)

Regent Pacific Seeks Shareholder Approval for New RSU Incentive Scheme

Endurance RP Sets Sights on China Approval and Longevity Tech Growth After 2025 Results

REGENT PACIFIC's wholly-owned subsidiary will launch its expansion plan into the United States in the first quarter of next year

REGENT PACIFIC released its interim results, reporting a net loss of USD 2.215 million, a year-on-year narrowing of 15.49%

REGENT PACIFIC: Jiangsu Wanbang Pharmaceutical is advancing the new drug application for SenstendTM with the National Medical Products Administration of China